Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cellsYulong Gao, Mark J. Smyth, Juming Yan et al.|Nature Immunology|2017Cited by 639
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor ImmunityXian-Yang Li, Mark J. Smyth, Achim K. Moesta et al.|Cancer Discovery|2019Cited by 269
Druggable epigenetic suppression of interferon-induced chemokine expression linked to <i>MYCN</i> amplification in neuroblastomaJohanna A Seier, Michael Hölzel|Journal for ImmunoTherapy of Cancer|2021Cited by 39
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanomaLuiza Martins Nascentes Melo, Iris Helfrich, Dayana Herrera-Rios et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 31
Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibitionLukas Flatz, Michael Hölzel|Research Square|2021Cited by 0